Table 4.
Comparison of baseline characteristics and outcomes of intermediate-risk patients treated with SAVR (2004–2010) and TAVR (2015–2017) at the Minneapolis VA Healthcare System (MVAHCS)
| MVAHCS TAVR Intermediate- risk (n=44) |
MVAHCS SAVR Intermediate-risk (n=142) |
P value |
|
|---|---|---|---|
| Age- years (±SD) | 80 (7) | 74 (9) | <0.01 |
| STS score, median | 5.2 | 5.5 | 0.9 |
| Men (%) | 42 (95.5%) | 141 (99%) | 0.09 |
| NYHA class III–IV | 29 (65%) | 114 (80%) | 0.04 |
| Previous MI | 8 (18%) | 51(36%) | 0.02 |
| Previous CABG | 15 (34%) | 18 (13%) | <0.01 |
| COPD | 20 (45%) | 67 (47%) | 0.81 |
| PAD | 8 (18%) | 75 (52%) | <0.01 |
| Creatinine (mg/dl)(±SD) | 1.1 (0.4) | 1.2 (0.6) | 0.30 |
| Hemoglobin g/dl (±SD) | 12 (1.9) | 13 (1.5) | <0.01 |
| Albumin g/dl(±SD) | 3.3 (0.5) | 4.1 (0.4) | <0.01 |
| Outcomes | |||
| Mortality | 0% | 10 (7%) | 0.07 |
| Stroke | 1 (2.2%) | 7 (4.9%) | 0.43 |
| Death or stroke | 1 (2.2%) | 17 (12%) | 0.05 |
| Length of stay –median in days (IQR) | 4 (3) | 11 (7) | <0.01 |
| New PPM | 11% | 4.9% | 0.14 |
| Moderate or Severe PVL | 6.8% | 3% | 0.26 |
STS: Society of Thoracic Surgeons, NYHA: New York Heart Association, COPD: chronic obstructive pulmonary disease, PAD: peripheral arterial disease, IQR: interquartile range